Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)

Boston, Massachusetts

We've found

1 trials

at this facility

A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Boston, MA

Use our guide to learn which trials are right for you!